The six-gate roadmap, Strategy Lock through Phase 2 Enablement, shows that the sequencing discipline built for one IND is what determines whether a company’s development engine can repeat for a second and third program.
White Paper
From IND to Phase 2: The 24 Months That Determine Whether Your Development Platform Scales
Related Resources
All Resources
post
Understanding FDA’s Real-Time Oncology Review (RTOR Medical Abbreviation) Program
Read More
white-paper
FDA CRLs Reveal a Pattern: Biologic Control Strategy Issues Drive Delays and Rejections
Read More
post
Building the Future of Breakthrough Therapies Together
Read More
post
When the Only Drug Runs Out: Lessons from the Bicillin® L-A Recall
Read More
Let's move from science to success.
Let’s Talk